[CITATION][C] Neuropeptide receptor imaging of schwannoma
H Van Steelandt, F De Geeter… - Journal of Nuclear …, 1996 - Soc Nuclear Med
Origin of Janus NeuropeptideReceptorImagingof Schwannoma Page 1 —,@ @ -_j:@ @ I @ @â€I
frequentlyused in its radiolabeledform for nuclear imaging. The absence of immunoreactivityon …
frequentlyused in its radiolabeledform for nuclear imaging. The absence of immunoreactivityon …
[PDF][PDF] Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging
JC Reubi - Journal of nuclear medicine, 1995 - Soc Nuclear Med
(5). Thereis, however, extensiveevidencethatshowsthatmost, if not all, of these
neuropeptides are also synthesized and act in non-neuronal tissues. The gut, with the brain …
neuropeptides are also synthesized and act in non-neuronal tissues. The gut, with the brain …
Somatostatin receptors in schwannomas
JC Reubi - The Journal of Nuclear Medicine, 1997 - search.proquest.com
TO THE EDITOR: In a recent letter to the Editor, van Steelandt et al.(I) reported that they
were able to detect somatostatin receptors in schwannomas using an indirect in vitro …
were able to detect somatostatin receptors in schwannomas using an indirect in vitro …
Radiopeptide imaging and therapy in Europe
V Ambrosini, M Fani, S Fanti, F Forrer… - Journal of Nuclear …, 2011 - Soc Nuclear Med
Receptor targeting with radiolabeled peptides has become an important topic, particularly in
nuclear oncology. Strong research efforts are under way in radiopharmaceutical science …
nuclear oncology. Strong research efforts are under way in radiopharmaceutical science …
Neuroendocrine tumors
Neuroendocrine tumors (NETs) originate from single or clustered neuroendocrine cells,
distributed in the gastrointestinal tract, urogenital tract, endocrine, and bronchopulmonary …
distributed in the gastrointestinal tract, urogenital tract, endocrine, and bronchopulmonary …
Update on nuclear medicine imaging of neuroendocrine tumors
SJ Goldsmith - 2009 - Future Medicine
Radiolabeled tracers provide a functional imaging technique to identify neuroendocrine
tumors, usually with greater sensitivity and specificity than anatomic imaging techniques …
tumors, usually with greater sensitivity and specificity than anatomic imaging techniques …
[HTML][HTML] Nuclear medicine imaging and therapy of neuroendocrine tumours
M Gotthardt, I Dijkgraaf, OC Boerman, WJG Oyen - Cancer Imaging, 2006 - ncbi.nlm.nih.gov
Radiolabelled peptides are used for specific targeting of receptors (over-) expressed by
tumour cells. Dependent on the kind of labelling and the radionuclide used, these …
tumour cells. Dependent on the kind of labelling and the radionuclide used, these …
[BOOK][B] Diagnostic and therapeutic nuclear medicine for neuroendocrine tumors
K Pacak, D Taïeb - 2016 - Springer
Diagnostic and therapeutic nuclear medicine for neuroendocrine tumors Series Editor: Leonid
Poretsky Contemporary Endocrinology Karel Pacak David Taïeb Editors Diagnostic and …
Poretsky Contemporary Endocrinology Karel Pacak David Taïeb Editors Diagnostic and …
[PDF][PDF] Peptide receptor radionuclide therapy with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors and meningioma: achieving two things in a single …
M Assadi, SJ Rekabpour, A Amini… - Molecular Imaging …, 2021 - pdfs.semanticscholar.org
We present a partial response of peptide receptor radionuclide therapy (PRRT) with 177Lu-
DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In …
DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In …
Neuro-ectodermal tumours
CA Hoefnagel - Clinical Nuclear Medicine, 1998 - Springer
Since its first reported use in humans in 1981 [1], 131 I-meta-iodobenzylguanidine (MIBG)
has been used with success for the scintigraphic diagnosis of a variety of neuroendocrine …
has been used with success for the scintigraphic diagnosis of a variety of neuroendocrine …